Feasibility of Dried Blood Spot (DBS) based screening method to establish the seroprevalence of Epstein-Barr- Virus (EBV) in a large population of young adults

Feasibility of Dried Blood Spot (DBS) based screening method to establish the seroprevalence of Epstein-Barr- Virus (EBV) in a large population of young adults - EBV Screening and Recruitment Feasibility Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033090

Enrollment

3000

Registered

2024-02-13

Start date

2023-11-28

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B27

Interventions

Group 1: During the EBV Screening and Recruitment Feasibility Study we plan to determine the feasibility of a DBS-based screening and recruitment strategy for future EBV studies. The study is designed

Eligibility

Sex/Gender

All

Age

18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Completion of Informed Consent Form

Exclusion criteria

Exclusion criteria: 1. Diseases and conditions that impede an Informed Consent 2. Insufficient command of the German language to a degree that impedes Informed Consent

Design outcomes

Primary

Measure	Time frame
To test the feasibility of a DBS-based screening and recruitment strategy for future EBV-studies.	—

Secondary

Measure	Time frame
1. Using a commercially available assay which detects EBV-specific antibodies in serum samples and evaluate if it can measure antibodies in a comparable manner in a different specimen, namely eluted DBS so that it can be used for epidemiological purposes 2. Assess the responsiveness of volunteers in a campaign with filter paper cards sent out via mail for blood self-collection 3. Establishment and testing of a simple, reliable and cost-effective screening method to identify EBV negative and positive individuals in the population 4. Estimate the EBV seroprevalence in a population of 18-25 years old individuals and ask for their general willingness to participate in potential future EBV research and studies.	—

Measure

Time frame

1. Using a commercially available assay which detects EBV-specific antibodies in serum samples and evaluate if it can measure antibodies in a comparable manner in a different specimen, namely eluted DBS so that it can be used for epidemiological purposes 2. Assess the responsiveness of volunteers in a campaign with filter paper cards sent out via mail for blood self-collection 3. Establishment and testing of a simple, reliable and cost-effective screening method to identify EBV negative and positive individuals in the population 4. Estimate the EBV seroprevalence in a population of 18-25 years old individuals and ask for their general willingness to participate in potential future EBV research and studies.

—

Countries

Germany

Contacts

Public ContactMirjam Schunk

Institut für Infektions- und Tropenmedizin, LMU Klinikum, LMU München

EBV-Studie@med.uni-muenchen.de+4989440059833

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026